• / Free eNewsletters & Magazine
  • / My Account
Home>Amgen Ends Psoriasis-Drug Partnership With AstraZeneca -- Update

Amgen Ends Psoriasis-Drug Partnership With AstraZeneca -- Update

3party Content

Sat, 23 May 2015

By Josh Beckerman Amgen Inc. said it is no longer working with AstraZeneca PLC on the co-development of brodalumab, a treatment for conditions including psoriasis, due to safety concerns. The biotechnology company said the decision was based on "events of suicidal ideation and behavior" that Amgen
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.